一项多中心研究评估单剂量低分子量右旋糖酐铁与单剂量非罗莫司治疗缺铁的有效性和安全性
这项多中心队列研究纳入906例接受单剂量低分子量右旋糖酐铁(LMWID,n=439)或非罗莫司(n=467)的患者,其中351例符合主要有效性终点。两组血红蛋白、血细胞比容和铁蛋白中位变化无显著差异,不良事件发生率相似,但LMWID组更多需要额外静脉铁输注。
要点
- 单剂量非罗莫司与LMWID在血红蛋白、血细胞比容和铁蛋白变化上无显著差异
- 两组不良事件发生率相似(LMWID 2.3% vs 非罗莫司 2.8%,P=0.63)
- LMWID组更频繁需要额外静脉铁输注(28.5% vs 16.1%,P<0.001)
核心结论
- 研究结果支持单剂量非罗莫司有效且安全,且与接受LMWID的患者相比,患者可能需要更少的额外输注。
研究设计与样本
- 多中心队列研究,纳入906例接受单剂量LMWID(n=439)或非罗莫司(n=467)的患者,其中351例符合主要有效性终点。
主要发现
- 血红蛋白中位变化:LMWID 0.5 g/dL vs 非罗莫司 0.8 g/dL,P=0.24,组间无显著差异。
- 血细胞比容中位变化:LMWID 1.1% vs 非罗莫司 1.25%,P=0.89,组间无显著差异。
- 铁蛋白中位变化:LMWID 87 ng/dL vs 非罗莫司 71 ng/dL,P=0.47,组间无显著差异。
- 不良事件发生率:LMWID 2.3% vs 非罗莫司 2.8%,P=0.63,组间无显著差异。
- 需要额外静脉铁输注的比例:LMWID 28.5% vs 非罗莫司 16.1%,P<0.001,LMWID组更频繁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are multiple intravenous (IV) iron formulations available, of which several may be administered as single-dose infusions such as low-molecular weight iron dextran (LMWID), ferumoxytol, ferric carboxymaltose, and ferric derisomaltose. However, administration of ferumoxytol as a single-dose infusion is off-label as it is approved as a two-dose series. Previous studies of ferumoxytol alone support the effectiveness and safety of the single-dose regimen, but there is a paucity of data directly comparing single-dose ferumoxytol to other single-dose IV iron formulations. This multicenter cohort study sought to affirm the safety and effectiveness of single-dose ferumoxytol compared to single-dose LMWID. Overall, 906 patients who received single-dose LMWID (n = 439) or ferumoxytol (n = 467) were identified, of whom 351 met criteria for the primary effectiveness endpoint defined as median change in hemoglobin (Hb), hematocrit (Hct), and ferritin 8 to 12 weeks from baseline. All 906 patients were included for the secondary analysis evaluating the incidence of adverse events (AE) and requirement of additional IV iron infusions. Median change in Hb (LMWID 0.5 g/dL; ferumoxytol 0.8 g/dL; P = .24), Hct (LMWID 1.1%; ferumoxytol 1.25%; P = .89), and ferritin (LMWID 87 ng/dL; ferumoxytol 71 ng/dL; P = .47) was not significantly different between groups. Both groups experienced similar rates of AEs (LMWID 2.3%; ferumoxytol 2.8%; P = .63). The LMWID patients more frequently required additional IV iron infusions (LMWID 28.5%; ferumoxtyol 16.1%; P < .001). These findings support that single-dose ferumoxytol is effective and safe, and that patients may require fewer additional infusions compared to patients who received LMWID.
引用
- Cohen J, Khudanyan A, Lu J, et al. A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency. Am J Hematol. 2020. PMID: 32918335. doi:10.1002/ajh.25995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。